- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00235521
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
Comparison of Inhaled Nitric Oxide With Aerosolized Iloprost (Ventavis®) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Investigators, Study Sites: Single-center trial at the Department of Pediatric Cardiology, Department of Cardiac Surgery and Department of Anesthesiology, University Medical Center, Heidelberg, Germany Exploratory proof of concept study (Investigator initiated trial)
Indication: Postoperative pulmonary hypertension in infants and children undergoing cardiopulmonary bypass surgery for intracardiac repair of left-to-right shunt
Objectives: To compare the efficacy of aerosolized iloprost with inhaled nitric oxide to prevent postoperative pulmonary hypertensive crises
Design: Exploratory, open label, randomized study with parallel-group design;
Duration of observation: 72 hours
Population: Infants older than 4 weeks and children less than 18 months of age presenting with left-to-right shunt and increased pulmonary blood flow. Inclusion will be independent on the presence or absence of preoperative pulmonary hypertension
Sample Size:
- 20 patients: inhaled nitric oxide (iNO) - group;
- 20 patients: aerosolized iloprost (ILO) -group
Treatment:
- Both groups: controlled ventilation, sedation, analgetics, inotropic substances as required, standardized intensive care treatment.
- iNO - group: concentration of iNO at 10 ppm; administered by mechanical ventilation.
- ILO - group: aerosolized Iloprost at a dose of 0,5 µg/kg body weight (12x / 24h), administered by ultrasound nebulizer.
Efficacy Parameters: Occurrence of "minor" or "major" pulmonary hypertensive crises (PHTC)
Safety Parameters: Arterial blood pressure, oxygen saturation, complete blood count
Statistical Procedures: All analyses in this exploratory trial are descriptive, giving confidence intervals for differences between treatment groups.
Primary analysis variable: Rate of occurrence of "major" or "minor" pulmonary hypertensive crises
Secondary variables: Presence of hours of pulmonary hypertension, Duration of mechanical ventilation
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Heidelberg, Germania, 69120
- University of Heidelberg, Medical Faculty, Department of Pediatric Cardiology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Informed consent by parents or legal representatives
- Age: Infants older than 4 weeks of age and children less than 1½ years of age.
Presence of a left-to-right shunt with increased pulmonary blood flow. The specific defects that will be present are:
- Aortopulmonary (AP) - Window
- Atrioventricular septal defect (AVSD)
- Double outlet right ventricle (DORV)
- Total anomalous pulmonary venous drainage (TAPVD)
- Truncus arteriosus
- Ventricular septal defect (VSD)
Presence of postoperative PH immediately after intracardiac repair:
- Patients will be enrolled if mean PAP after intracardiac repair exceeds 25 mmHg after weaning from CPB.
Exclusion Criteria:
Specific cardiac defects:
- Atrial septal defect (ASD)
- Cyanotic congenital heart disease
- Univentricular atrio-ventricular - connexion
- Valvular or subvalvular pulmonary or aortic stenosis
Specific circumstances:
- Emergency cardiac surgery
- Children presenting with infection after cardiac surgery
- Infants on extracorporeal membrane oxygenation (ECMO) before cardiac surgery
- Infants/children treated with epoprostenol
Concomitant diseases:
- Systemic arterial hypertension
- Renal failure
- Diabetes mellitus
- Known bleeding disorders (known disorders of blood coagulation and hemostasis)
- Infection during the first 24 hours after cardiac surgery
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
---|
Number of pulmonary hypertensive crises (major and/or minor)
|
Misure di risultato secondarie
Misura del risultato |
---|
Treatment with aerosolized ILO is equally effective as iNO in reducing the pulmonary artery pressure (PAP) within the first 72 hours after cardiopulmonary bypass surgery (CPB)
|
Patients treated with aerosolized ILO can be weaned earlier from mechanical ventilation than patients on iNO treatment
|
Patients treated with aerosolized ILO show the same in-hospital mortality as patients treated with iNO
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Matthias Gorenflo, MD, PhD, Heidelberg University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Iloprost-Study
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su aerosolized iloprost
-
University of OklahomaCompletatoBroncopneumopatia cronica ostruttiva | Ipertensione polmonareStati Uniti
-
ActelionTerminatoIpertensione arteriosa polmonareStati Uniti
-
ActelionTerminatoIpertensione polmonareStati Uniti
-
Loma Linda UniversityRitiratoVasocostrizione polmonare ipossicaStati Uniti
-
National Center for Research Resources (NCRR)University of PittsburghCompletatoSclerosi sistemica | Malattia di Raynaud
-
Charite University, Berlin, GermanySchering-PloughTerminatoSclerosi sistemicaGermania
-
Lund University HospitalBayerRitiratoSindrome da stress respiratorio | Ipertensione polmonare persistenteSvezia
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletatoCancro ai polmoni | Condizione precancerosaStati Uniti
-
BayerCompletatoIpertensione, polmonareItalia, Spagna, Francia, Germania, Portogallo, Regno Unito
-
BayerCompletatoIpertensione polmonareCorea, Repubblica di